Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer

• Published in: The Prostate Vol. 82; no. 8; pp. 911 - 916
• Main Authors: Lundgren, Per‐Olof, Tribukait, Bernhard, Kjellman, Anders, Norming, Ulf, Jagarlmudi, Kiran, Gustafsson, Ove
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2022; John Wiley and Sons Inc
• Subjects: Biomarkers; Biomarkers, Tumor; Case-Control Studies; Cell division; Death; Humans; Male; Medicin och hälsovetenskap; Mortality; Original; prognosis; Prostate cancer; Prostatic Neoplasms; Thymidine; Thymidine Kinase; thymidine kinase; prognosis; prostate cancer
• ISSN: 0270-4137; 1097-0045; 1097-0045
• DOI: 10.1002/pros.24335

Background Thymidine kinase 1 (TK1) recycles DNA before cell division. We do not know if baseline blood concentrations of TK1 predict death in prostate cancer within 30 years. Our objective is to determine if there is an association between baseline levels of TK1 and future prostate cancer‐specific mortality. Methods With a “proof of concept” approach, we performed a nested case–control study among 1782 individuals screened for prostate cancer between 1988 and 1989. The concentration of TK1 was measured in frozen serum from 330 men, 36 of whom have died of prostate cancer. The primary endpoint was prostate cancer‐specific mortality and outcomes after 30 years were analyzed using logistic regression modeling odds ratios (Ors). Results The estimated OR (adjusted for age) for dying from prostate cancer among the men who had a TK1 value in the upper tertile was 2.39 (95% confidence interval 1.02–5.63). The corresponding OR, regardless of the cause of death, was 2.81 (1.24–6.34). Conclusions High levels of TK1 predicts death in prostate cancer within 30 years of follow‐up.